pegfilgrastim-jmdb Fulphila
Selected indexed studies
- Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. (J Med Econ, 2021) [PMID:33866947]
- Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study. (J Manag Care Spec Pharm, 2023) [PMID:36705287]
- Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar. (BioDrugs, 2019) [PMID:30701419]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar. (2019) pubmed
- Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment. (2021) pubmed
- Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study. (2023) pubmed
- Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population. (2022) pubmed